Vaccine

(RED) KICKS-OFF (LIVE SUMMER): A CAMPAIGN TO FIGHT AIDS & COVID

Retrieved on: 
Wednesday, June 29, 2022 - 10:28pm
Knowledge, Honey, KISS, ANOVA, Pandemic, COVID-19, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Mark R. Dybul, Apple, FIAT, YouTube, Chase, PayPal, Roche, Citigroup, Vaccine, Heat, American Express, STYLE, Global health, Color, Analysis of variance, A Barefoot Dream, AIDS, COO, Bank of America, Nail, Eos, Woman, Merck, Investment, WITH, JEEP, RED, Twitter, Gavi, Ai, Azienda Elettrica Ticinese, CEO, Mavin Records, COVID, Girl Distribution Company, Vespa, Health care, HIV, Public sector, Partnership, Salesforce, Fiat, Anova Culinary, ViiV Healthcare, Multimedia, Bank, USD, Starbucks, Jeep, AMC, UNAIDS, Bono, Wells Fargo, Private sector, Honeypot, Awareness, RAM, Government, Cryptocurrency, Pharmaceutical industry, Tuberculosis, Malaria, Amazon, Primark, Policy, DRIVE

NEW YORK, June 29, 2022 /PRNewswire/ -- This summer, (RED), the organization co-founded by Bono and Bobby Shriver, is launching '(LIVE SUMMER)', a campaign to fight AIDS and COVID-19. There are many ways to be (RED) - from what's in your makeup kit to cooking-up a storm in the kitchen or hitting the road for a summer drive - and, through August 4, (RED) alongside its partner brands will present a variety of activations that raise money and awareness to ensure testing, treatment, and vaccines are available to everyone, everywhere.

Key Points: 
  • As part of the launch, Barefoot Dreams and (RED) will share the best ways to RELAX (RED) this summer.
  • To celebrate the launch of the new The Ridge (PRODUCT)RED wallet, The Ridge will engage fans and followers with an exciting Twitter campaign.
  • For every retweet of a designated post, The Ridge will make a donation to support (RED) in the fight against global health emergencies.
  • "The fight to end AIDS and COVID-19 will not be won without continued support from the private sector, to further bolster public sector efforts.

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Retrieved on: 
Wednesday, June 29, 2022 - 9:45pm
Emergency Use Authorization, Annual report, Science, Hoffmann-La Roche, LinkedIn, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Peer review, Research, DO, Marketing, COVID-19, Cancer, Company, U.S. Securities and Exchange Commission, Omicron, Regeneron Pharmaceuticals, Pierre Geneves, Awareness, Infection, Publication, Risk, YouTube, Clinical trial, Private Securities Litigation Reform Act, News, SEC, Facebook, BioNTech, Immunotherapy, Vaccine, Government, EUA, Safety, Twitter, Vaccination, Pediatrics, Program, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Retrieved on: 
Wednesday, June 29, 2022 - 9:30pm
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Washington metropolitan area, FDA, University of North Carolina at Greensboro, Patient, LinkedIn, Engineering, Regulatory affairs, Edit, R, Society, SAB, Access, Center for Biologics Evaluation and Research, United States Air Force Scientific Advisory Board, Chapel Hill, Founder, Therapy, DABT, Gene editing, Drug discovery, RAC, RNA, Genome, Technology, Center, RAPS, SOT, University, Rgn, American College of Toxicology, Arnold, American College, Twitter, Duke University, Doctor of Philosophy, Pharmaceutical industry, Vaccine, FRAPS, Toxicology, Biochemistry, Research

Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).

Key Points: 
  • Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).
  • We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio.
  • Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.
  • About Life Edit Therapeutics Inc.
    Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors.

First Trust Advisors L.P. Announces Distribution for First Trust Enhanced Short Maturity ETF

Retrieved on: 
Wednesday, June 29, 2022 - 9:05pm
Professional Services, Finance, Volatility, ERISA, Financial Conduct Authority, Investment, London Interbank Bid Rate, FINRA, Internal Revenue Code, Index, Credit, COVID-19, Judgement, Respiratory disease, Disease, Risk, FTA, Federal Deposit Insurance Corporation, Prospectus, LIBOR, Face, Infection, Terrorism, United Kingdom, ETF, Asset-backed security, Technology, Loss, Adviser, AIB (NI), Time, Vaccine, FTP, Internal Revenue Code section 409A, Income, Financial adviser, Bank, Security (finance), Fund

First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.

Key Points: 
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.
  • FTA and its affiliate First Trust Portfolios L.P. ("FTP"), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services.
  • Volatility is the characteristic of a security, an index or a market to fluctuate significantly in price within a short time period.
  • Such exposures could cause the Fund's net asset value to experience significant increases or declines in value over short periods of time.

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Retrieved on: 
Wednesday, June 29, 2022 - 9:45pm
Biotechnology, General Health, COVID-19, Health, Pharmaceutical, Emergency Use Authorization, Annual report, Science, Hoffmann-La Roche, LinkedIn, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Peer review, Research, DO, Marketing, COVID-19, Cancer, Company, U.S. Securities and Exchange Commission, Omicron, Regeneron Pharmaceuticals, Pierre Geneves, Awareness, Infection, Publication, Risk, YouTube, Clinical trial, Private Securities Litigation Reform Act, News, SEC, Facebook, BioNTech, Immunotherapy, Vaccine, Government, EUA, Safety, Twitter, Vaccination, Pediatrics, Program, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services

Retrieved on: 
Wednesday, June 29, 2022 - 6:00pm
Water, FDA, Fed, Process, CEO, USD, CGMP, Immortalised cell line, GLOBE, Mitsubishi Corporation, Fujifilm, Diosynth, Growth, CO2, CDMO, Bioreactor, United Kingdom, Technology, A-DNA, Natural gas, Triangle Park (Quezon City), Antibody, College Station, Solution, Vaccine, Knowledge, Fine chemical, Innovation

TOKYO, June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO).

Key Points: 
  • TOKYO, June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO).
  • This investment will enhance FUJIFILM Diosynth Biotechnologies sites in Hillerd, Denmark, and Texas in the United States.
  • This investment will also expand cell culture manufacturing solutions at the FUJIFILM Diosynth Biotechnologies Texas site.
  • FUJIFILM Diosynth Biotechnologies will implement its proprietary SymphonXTM production equipment, enabling cGMP MaruX continuous processing at the single-use cell culture manufacturing site.

Global Blood Group Typing Market Analysis to 2029 - Featuring Ortho Clinical Diagnostics, Quotient, Novacyt and Rapid Labs Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022 - 5:13pm
Health, General Health, Biotechnology, Conditional sentence, Laboratory, Accident, Forensic Science Service, Organ transplantation, Trauma, CAGR, ABO, HLA, Incidence, PCR, Government, Knowledge, Income, Vaccine, Fine chemical, Growth

Growth in global number of road accidents and trauma cases requiring blood transfusions is a key driver for the growth of the global blood group typing market.

Key Points: 
  • Growth in global number of road accidents and trauma cases requiring blood transfusions is a key driver for the growth of the global blood group typing market.
  • Additionally, increase in demand for blood group typing in prenatal testing and rise in application of blood group typing in forensic sciences are some of the other drivers propelling the market growth.
  • Nevertheless, high cost of blood group typing and lack of knowledge regarding blood group typing among developing economies are expected to restrain the global market growth.
  • Based on test type, the market is categorized into ABO blood tests, antibody screening, HLA typing, antigen typing, and cross-matching tests.

Panitch Schwarze Partners Named Among 2022 IAM Patent 1000

Retrieved on: 
Wednesday, June 29, 2022 - 5:15pm
Hirschhorn, Dunston, LLP, PTAB, Patent Trial and Appeal Board, IAM, USPTO, IP, Radiation, Patent, Belisario, Vaccine, Lawyer, Knowledge, Pharmaceutical industry

PHILADELPHIA, June 29, 2022 /PRNewswire-PRWeb/ -- Panitch Schwarze Belisario & Nadel LLP is pleased to announce that intellectual property attorneys Martin G. Belisario, Erin M. Dunston and Philip L. Hirschhorn were recently named part of the IAM Patent 1000. Belisario is ranked for transactions, and Dunston and Hirschhorn are ranked for litigation. Dunston is also ranked for her work in prosecution.

Key Points: 
  • PHILADELPHIA, June 29, 2022 /PRNewswire-PRWeb/ -- Panitch Schwarze Belisario & Nadel LLP is pleased to announce that intellectual property attorneys Martin G. Belisario , Erin M. Dunston and Philip L. Hirschhorn were recently named part of the IAM Patent 1000.
  • Dunston focuses her practice on patent procurement, opinions, enforcement (both in district courts and before the Patent Trial and Appeal Board), and portfolio strategy.
  • IAM Patent 1000 is commonly regarded as the definitive 'go-to' resource for those seeking to identify world-class, private practice patent expertise and leading expert witnesses in the US.
  • About Panitch Schwarze Belisario & Nadel LLP Panitch Schwarze Belisario & Nadel LLP is a boutique intellectual property law firm with offices in Philadelphia and Wilmington, Delaware.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022 - 3:20pm
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Fujifilm Celebrates Four Recent Recipients of Fujifilm Fellowship at Harvard Medical School

Retrieved on: 
Wednesday, June 29, 2022 - 4:25pm
System, Disease, Patient, Information, Research, GLOBE, Fujifilm, Cancer, University Hospital Heidelberg, Mouse Models of Human Cancer database, FUJIFILM, Doctor of Philosophy, Knowledge, Harvard Medical School, Cell, Department, Student, Entrepreneurship, Pharmacology, Toxicology, Infection, Therapy, Biology, Photography, Education, Harvard T.H. Chan School of Public Health, Harvard University, Malaria, Dana–Farber Cancer Institute, Hospital, Public health, Plasmodium, Genetics, Drug discovery, Sale, Gene expression, Curriculum, Biomedical sciences, HMS, Massachusetts General Hospital, Program, Medicine, Management, Vaccine, Pharmaceutical industry, Innovation, Molecule

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced that four doctoral students have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS).

Key Points: 
  • CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced that four doctoral students have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS).
  • The mission of the program is to equip promising scientists with the specialized skills needed to translate their research findings into next-generation medical solutions for patients.
  • Specifically, the program awards two years of research funding to students from across the nine HMS-based life sciences Ph.D. programs.
  • The Fujifilm Fellowship program was designed by Fujifilm and HMS to advance translational medicine research by investing in the next-generation of scientists.